Centauri Therapeutics
Agent42Agent Readiness: 42/100. Above median. Measured by StartupHub.ai. Median 41.Trust81Data Trust: 81/100. Top 25%. Measured by StartupHub.ai. Median 61.Developing novel Alphamer® therapeutics to combat serious diseases, with a primary focus on antimicrobial resistance (AMR).
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
Centauri Therapeutics is a biotechnology company based in Alderley Park, UK, focused on the discovery and development of novel therapeutics for serious diseases. Leveraging its proprietary Alphamer® platform, the company develops immunotherapies that harness the body's natural immune response to fight life-threatening infections, particularly multi-drug resistant Gram-negative bacteria. The platform also has initial proof-of-concept data in oncology, expanding therapeutic options for vulnerable patients.
Similar companies
Biotechnology company developing novel protein-based antimicrobial therapeutics.
Shares Biotechnology, Pharmaceuticals
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Pharmaceuticals
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Pharmaceuticals
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- centauritherapeutics.com
- Headquarters
- Oxford, England, United Kingdom
- Founded
- 2013
- Total funding
- $57M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Post-money | Lead investors |
|---|---|---|---|---|
| 24 Feb 2026 | Series A | $8M | $38M | AMR Action Fund |
| 29 Jul 2025 | Grant | $5M | ||
| 26 Nov 2024 | Grant | $1M | ||
| 24 Feb 2024 | Series A | $8M | AMR Action Fund | |
| 16 Feb 2022 | Series A | $30M | ||
| 1 Dec 2019 | Grant | $1M | ||
| 18 Jan 2016 | Seed | $4M |
Tech stack
Detected on centauritherapeutics.com, last scanned 24 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
- Cookie consent
- Cookiebot
Centauri Therapeutics scores 29. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Centauri Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Centauri Therapeutics is 81 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Centauri Therapeutics raised?
Centauri Therapeutics has raised a total of $57M in funding. The most recent round on record is Series A.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Centauri Therapeutics
